Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study-Reference-Cited by-同舟云学术

Comparison of an AC‐taxane versus AC‐free regimen and paclitaxel versus docetaxel in patients with lymph node‐positive breast cancer: Final results of the National Surgical Adjuvant Study of Breast Cancer 02 trial, a randomized comparative phase 3 study

Published:2017-01-12 Issue:5 Volume:123 Page:759-768
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Watanabe Toru¹,Kuranami Masaru²,Inoue Kenichi³,Masuda Norikazu⁴,Aogi Kenjiro⁵,Ohno Shinji⁶,Iwata Hiroji⁷,Mukai Hirofumi⁸,Uemura Yukari⁹,Ohashi Yasuo¹⁰

Affiliation:

1. Department of Medical OncologyHamamatsu Oncology CenterHamamatsu Japan

2. Department of SurgeryYamato Municipal HospitalYamato Japan

3. Breast Oncology, Saitama Cancer CenterKita‐Adachi Japan

4. Division of Breast SurgeryDepartment of Surgery, National Hospital Organization Osaka National HospitalOsaka Japan

5. Department of Breast OncologyNational Hospital Organization Shikoku Cancer CenterMatsuyama Japan

6. Breast Oncology Center, Cancer Institute Hospital of the Japanese Foundation of Cancer ResearchTokyo Japan

7. Department of Breast OncologyAichi Cancer Center HospitalNagoya Japan

8. Department of Oncology and HematologyNational Cancer Center Hospital EastKashiwa Japan

9. Clinical Research Support Center (CresCent)The University of Tokyo HospitalTokyo Japan

10. Department of Integrated Science and Engineering for Sustainable SocietyChuo UniversityTokyo Japan

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.30421

Reference14 articles.

1. Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer

2. Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial;Buzdar AU;Clin Cancer Res,2002

3. Paclitaxel After Doxorubicin Plus Cyclophosphamide As Adjuvant Chemotherapy for Node-Positive Breast Cancer: Results From NSABP B-28

4. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100 000 women in 123 randomised trials

5. Risk Factors for Doxorubicin-lnduced Congestive Heart Failure

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of systemic dexamethasone dosage on docetaxel-induced oral mucositis in patients with breast cancer;Scientific Reports;2023-06-22

2. High dose of dexamethasone attenuates docetaxel-induced fluid retention in breast cancer treatment;Scientific Reports;2023-06-07

3. Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100 000 women from 86 randomised trials;The Lancet;2023-04

4. Hematologic Toxicities and its Determinants among Breast Cancer Patients Treated with Doxorubicin-Cyclophosphamide Followed by Paclitaxel Regimen in Cancer Centers: Retrospective Cohort Study;2023-03-13

5. The impact of single nucleotide polymorphisms on return-to-work after taxane-based chemotherapy in breast cancer;Cancer Chemotherapy and Pharmacology;2023-01-04